Raphael Ognar | President & Chief Executive Officer, Co-Founder
NKILT Therapeutics Inc.

Pharma/Biotech executive with over 25 years of commercial, drug development, product lifecycle and strategy expertise, including 20 years in Oncology. Throughout his career, he built extensive expertise in Oncology/Hematology and acquired leadership skills through country and global roles in commercial, pipeline management, drug development, and strategy. For the last decade, his efforts concentrated in Immuno-Oncology and Cell Therapy technologies. In 2018, Raphaël created ANIM8 LLC, an executive strategy & operations consulting company, to support early-stage Biotechs, essentially in Immuno-Oncology and Cell Therapy, but also Digital Health / RWE startups. In Summer 2021, he founded NKILT Therapeutics, Inc. to build, with his co-founders, a novel and disruptive allogeneic cell therapy technology based on an innovative binding approach. The company is launching its Series A and their IND process and dialog with FDA. Raphaël has a Masters and D.E.A. of Physiology and Neurosciences from University of Bordeaux I&II, and an MBA in Strategic Marketing and Enterprise Management from I.A.E Tours University. Besides fighting cancer, his passions are vintage wines, playing music in his family band, pushing himself rock climbing and traveling the world with family and friends.